Brenda Huneycutt is a director at FasterCures, a center of the Milken Institute, where she leads the “Enabling a High-Performing Biomedical Ecosystem” program and directs a project portfolio aimed at creating a system that works better for patients. Her work includes developing a biomedical ecosystem performance scorecard, creating tools to increase the representation of patient perspectives in health care decision-making, and driving transparency in medical product development.
Prior to joining FasterCures, Dr. Huneycutt was vice president, regulatory strategy and FDA policy at Avalere Health, advising organizations on topics such as patient engagement in drug development, compassionate use/expanded access to investigational products, regulatory exclusivities, the Food and Drug Administration’s orphan drug and expedited programs, and the use of real-world evidence in regulatory decision-making. Dr. Huneycutt has also practiced as a patent lawyer in a large firm working on pharmaceutical litigation, and spent many years as a research scientist, primarily studying cell division and cell cycle control in yeast model systems. Dr. Huneycutt holds a PhD in molecular biology from the University of Colorado at Boulder, a JD from the George Washington University School of Law, and an MPH from the Johns Hopkins University Bloomberg School of Public Health.